Article
Dermatology
Merav Koschitzky, Kristina Navrazhina, Michael S. Garshick, Juana Gonzalez, Joseph Han, Sandra Garcet, James G. Krueger
Summary: This study aimed to identify biomarkers of cardiovascular (CV) risk in psoriasis blood that are reduced by ustekinumab. The results showed that 43 out of 276 proteins were down-regulated after treatment, and 8 of them were initially elevated above thresholds associated with enhanced CV risk.
EXPERIMENTAL DERMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yu-Huei Huang, Lun-Ching Chang, Ya-Ching Chang, Wen-Hung Chung, Shun-Fa Yang, Shih-Chi Su
Summary: Alterations in gut microbiota composition and microbial-encoded metabolic pathways were observed in patients with psoriasis, and the impact of biologics on shaping gut microbiota was explored in this study. The results showed that the gut microbial compositions changed during the treatment period, and the relative abundance of individual taxa differed between patients receiving different inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Gianluca Avallone, Carlo Alberto Maronese, Giulia Murgia, Carlo Giovanni Carrera, Luca Mastorino, Gabriele Roccuzzo, Paolo Dapavo, Silvia Alberti-Violetti, Pietro Quaglino, Simone Ribero, Angelo Valerio Marzano
Summary: This study aimed to compare the efficacy of IL-17 and IL-23 inhibitors in treating pustular and erythrodermic psoriasis. The results showed that IL-17 inhibitors had higher effectiveness in treating these conditions, while the efficacy of IL-23 inhibitors remains unknown.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Evelyn Kelemen, Eva Adam, Stella Marta Sagi, Aniko Goblos, Lajos Kemeny, Zsuzsanna Bata-Csorgo, Marta Szell, Judit Danis
Summary: Psoriasis is a chronic inflammatory skin disease influenced by both genetic and environmental factors. Increased levels of free nucleic acids in psoriatic skin are associated with IL-23 expression. The study reveals that free nucleic acids regulate IL-23 mRNA expression in epithelial keratinocytes through TLR3 receptor and specific signaling pathways, contributing to the development of an inflammatory milieu favorable for psoriatic symptoms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dermatology
Xingyu Zhu, Ruomei Han, Xiaoxue Tian, Mathias Hochgerner, Hui Li, Jiucun Wang, Jingjing Xia
Summary: Tapinarof has different effects on different types of psoriasis, inhibiting the development of IMQ-induced psoriatic dermatitis while aggravating the IL-23-injection model. This suggests that Tapinarof may have varying effects on different psoriasis subtypes.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Rheumatology
Josef S. Smolen, Stefan Siebert, Tatiana Korotaeva, Carlo Selmi, Paul Bergmans, Elisa Gremese, Beatriz Joven-Ibanez, Gkikas Katsifis, Wim Noel, Michael T. Nurmohamed, Pascal Richette, Petros P. Sfikakis, Kurt de Vlam, Elke Theander, Laure Gossec
Summary: The 6-month effectiveness of ustekinumab and TNFi in treating PsA patients was similar, with high baseline body mass index and cDAPSA score associated with lower chance of achieving cDAPSA LDA with TNFi. Predictive factors were consistent with previous evidence, and safety data were comparable between the two treatment groups.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Dermatology
Mariolina Bruno, Linda Davidson, Hans J. P. M. Koenen, Juul M. P. A. van den Reek, Bram van Cranenbroek, Elke M. G. J. de Jong, Frank L. van de Veerdonk, Bart-Jan Kullberg, Mihai G. Netea
Summary: Biologics that block the Th17 pathway are effective in treating inflammatory diseases like psoriasis but may increase the risk of Candida infections. This study found that patients with psoriasis receiving IL-17 inhibitors had impaired immune responses, leading to reduced antifungal defense and increased susceptibility to candidiasis.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Dermatology
Claudio Bonifati, Aldo Morrone, Antonio Cristaudo, Dario Graceffa
Summary: New biologic drugs targeting interleukin-17 have shown quick effectiveness in treating psoriasis, but there is limited real-life data on switching to biologics targeting interleukin-23 in patients who have failed previous treatments.
DERMATOLOGIC THERAPY
(2021)
Review
Dermatology
Alan Menter, Gerald G. Krueger, So Yeon Paek, Dario Kivelevitch, Iannis E. Adamopoulos, Richard G. Langley
Summary: Psoriasis is an immune-mediated inflammatory skin disease associated with inflammatory comorbidities, including increased cardiovascular risk. The IL-23/IL-17 axis plays a central role in the immunopathogenesis of psoriasis and related comorbidities, and selectively inhibiting these cytokines has significant therapeutic benefits for patients with moderate to severe plaque psoriasis.
DERMATOLOGY AND THERAPY
(2021)
Review
Dermatology
Alice B. Gottlieb, Daniel Saure, Stefan Wilhelm, Martin Dossenbach, Christopher Schuster, Saxon D. Smith, Yuval Ramot, Diamant Thaci
Summary: This study compared the speed of onset and level of skin improvement between the IL-17A antagonist ixekizumab and the IL-23 p19 inhibitors guselkumab, tildrakizumab, and risankizumab in patients with moderate-to-severe plaque psoriasis. The results showed that ixekizumab had a faster onset of effect and greater clinical benefits than the IL-23 p19 inhibitors up to week 12.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Medicine, Research & Experimental
Jiun-Wen Guo, Yu-Pin Cheng, Chih-Yi Liu, Haw-Yueh Thong, Yang Lo, Chen-Yu Wu, Shiou-Hwa Jee
Summary: Magnolol, a polyphenolic compound, has been shown to have therapeutic effects in dermatological processes, but its application in psoriasis research is limited. The study demonstrated that downregulation of IL-23 by magnolol may contribute to improvement in barrier function in psoriatic skin models.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Wangda Zhou, Chuanpu Hu, Yaowei Zhu, Bruce Randazzo, Michael Song, Amarnath Sharma, Zhenhua Xu, Honghui Zhou
Summary: A population pharmacokinetic model and a joint longitudinal exposure-response model were developed to characterize the PK and exposure-response relationship of ustekinumab in pediatric patients with psoriasis. The models predicted the PK of ustekinumab and the clinical response in pediatric patients with psoriasis, showing efficacy and safety in this population.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Dermatology
Piyu Parth Naik
Summary: Anti-IL-23 agents used to treat psoriasis can cause a range of adverse effects, with the most common being nasopharyngitis, headache, upper respiratory tract infection, and back pain. Certain specific anti-IL-23 agents may be associated with more severe adverse effects.
Review
Gastroenterology & Hepatology
Sudheer Kumar Vuyyuru, Virginia Solitano, Malcolm Hogan, John K. MacDonald, Alexa Zayadi, Claire E. Parker, Bruce E. Sands, Remo Panaccione, Neeraj Narula, Brian G. Feagan, Siddharth Singh, Vipul Jairath, Christopher Ma
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of selective IL-23p19 and IL-12/23p40 inhibitors in patients with moderate-to-severe CD. The results demonstrated that targeting IL-23 is effective and safe for inducing and maintaining clinical and endoscopic remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Dermatology
Tiago Torres, Luis Puig, Ron Vender, Charles Lynde, Stefano Piaserico, Jose M. Carrascosa, Paolo Gisondi, Esteban Dauden, Curdin Conrad, Pedro Mendes-Bastos, Paulo Ferreira, Luiz Leite, Justin D. Lu, J. Valerio, M. Bruni, F. Messina, A. Nidegger, M. Llamas-Velasco, E. del Alcazar, A. Mufti, Kyra White, G. Caldarola, Laetitia Teixeira, Paolo Romanelli, K. Desai, Spyridon Gkalpakiotis, Marco Romanelli, Jensen Yeung, Miguel Nogueira, Andrea Chiricozzi
Summary: In this study, drug survival analysis of the most recent biologic agents approved for the treatment of psoriasis was conducted. Factors such as female sex, higher BMI, and prior exposure to biologic agents were found to significantly increase the risk of drug discontinuation. The study also showed that the drug survival of guselkumab and risankizumab was higher than that of ustekinumab, while secukinumab had a lower drug survival rate.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2021)
Article
Dermatology
Hsien-Yi Chiu, Rosaline Chung-Yee Hui, Tsen-Fang Tsai, Yang-Ching Chen, Nien-Feng Chang Liao, Po-Hua Chen, Po-Ju Lai, Ting-Shun Wang, Yu-Huei Huang
Summary: This study investigates the predictors of relapse in psoriasis patients after discontinuation of ustekinumab treatment. The results show that being biologic-naive, maximum improvement in Psoriasis Area and Severity Index during ustekinumab treatment, time to achieve a 50% improvement in baseline Psoriasis Area and Severity Index score after initiation of ustekinumab, family history of psoriasis, chronic kidney disease, and immunosuppressant use while not taking ustekinumab are significant predictors of relapse time following discontinuation of ustekinumab.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Letter
Dermatology
Jen-Ping Chao, Jing-Yi Lin, Cheng-Ying Chiang, Tyng-Shiuan Hsieh, Sung-Jan Lin, Jin-Bon Hong
JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Hsien-Yi Chiu, Wei-Hung Wang, Chen-Hsiang Kuan, Yueh-Feng Wu, Chung-Jen Tseng, Wen-Yen Huang, Shiou-Han Wang, Sung-Jan Lin
Summary: This study investigates the mechanism of permanent hair loss induced by depilatory laser and reveals the role of thermal diffusion. The results showed that laser treatment leads to hair miniaturization due to thermal necrosis of dermal papilla cells caused by thermal diffusion from melanin-containing cells.
LASERS IN SURGERY AND MEDICINE
(2022)
Article
Medicine, General & Internal
Ching-Chi Chi, Yen-Wen Wu, Ting-Hsing Chao, Chih-Chiang Chen, Yi-Ju Chen, Hao-Min Cheng, Hsien-Yi Chiu, Yu-Wei Chiu, Wen-Hung Chung, Tsu-Yi Hsieh, Po-Hsun Huang, Yu-Huei Huang, Shang-Hung Lin, Tsung-Hsien Lin, Kwo-Chang Ueng, Chun-Chieh Wang, Yu-Chen Wang, Nan-Lin Wu, Charles Jia-Yin Hou, Tsen-Fang Tsai
Summary: Psoriatic disease, a chronic inflammatory disorder with skin and joint manifestations, is associated with an increased risk of cardiovascular diseases due to the shared pathogenic mechanisms between psoriatic and CV diseases. Therefore, attention to cardiovascular comorbidities is crucial in the management of psoriasis, particularly in screening, primary prevention, and treatment selection. The collaboration between dermatology, cardiology, and rheumatology experts has led to consensus expert recommendations for the management of patients with psoriatic disease with a focus on CV comorbidities.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Chemistry, Multidisciplinary
Kai-Chiang Yu, Chun-Yao Hsu, Gurpur Rakesh D. Prabhu, Hsien-Yi Chiu, Pawel L. Urban
Summary: Skin metabolites have great potential for clinical diagnostics, but current skin sampling and analysis workflows are time-consuming. In this study, we present a vending-machine-style skin excretion sensing platform that uses hydrogel-assisted sampling. The platform involves a robotic arm holding a sampling probe with hydrogel, which is pressed onto the forearm of a human subject. Water-soluble metabolites are collected into the hydrogel, while nonpolar metabolites are left behind. The collected metabolites are then extracted and analyzed using a mass spectrometer, with the results displayed on a graphical user interface.
Article
Chemistry, Analytical
Decibel P. Elpa, Chamarthi Maheswar Raju, Hsien-Yi Chiu, Shu-Pao Wu, Pawel L. Urban
Summary: A facile and rapid skin metabolomics protocol using a liquid microjunction-surface sampling probe system and hydrogel probes has been proposed. The method has been validated for the analysis of choline as a putative biomarker of psoriasis, and potential biomarkers including choline, pipecolic acid, ornithine, urocanic acid, and methionine have been identified. The developed method provides a quick and accurate analysis of skin metabolites in a clinical setting.
ANALYTICA CHIMICA ACTA
(2023)
Review
Dermatology
Sung-Jan Lin, Zhicao Yue, Ralf Paus
Summary: This article describes the clinical manifestation and pathobiology of radiotherapy-induced alopecia (RIA), emphasizing the importance of studying the principles of human organ and stem cell repair, regeneration, and loss. The article discusses the response of different hair follicle and extrafollicular cell populations to radiation, their roles in hair follicle repair and regeneration, and how they contribute to hair follicle miniaturization or even loss in persistent RIA. Finally, the article highlights the potential of targeting various pathways in future RIA management.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Letter
Dermatology
I-Ling Chen, Hsien-Yi Chiu
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Letter
Dermatology
Y. T. Chen, H. Y. Chiu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Pharmacology & Pharmacy
Ya-Chu Tsai, Chen-Yiu Hung, Tsen-Fang Tsai
Summary: Recommendations on selecting biologics and targeted synthetic small molecules for refractory HS can be made by comparing the efficacy and safety of these medications. Adalimumab, bimekizumab, secukinumab 300 mg q4w, and secukinumab 300 mg q2w showed superior outcomes compared to placebo in terms of HiSCR at 12-16 weeks. There were no significant differences between bimekizumab and adalimumab in terms of HiSCR and DLQI 0/1.
Article
Biochemistry & Molecular Biology
I-Heng Chiu, Tsen-Fang Tsai
Summary: Ixekizumab (Taltz(®)) is a humanized anti-IL-17A monoclonal antibody used to treat inflammatory diseases. Overweight or obesity may be protective against ixekizumab-induced injection site reactions, while a positive family history of psoriasis may be a potential risk factor. Additionally, patients experiencing diarrhea after ixekizumab injection are at higher risk for developing injection site reactions.
Article
Dermatology
Wei-Hung Wang, Raul Ramos, Kang-Yu Tai, Yun-Shan Wu, Tso-Yu Chang, Jia-Yu Yan, Maksim V. Plikus, Ji Won Oh, Sung-Jan Lin
Summary: Researchers should take into account the impact of the hair growth cycle on the interpretation of dermatological studies. Hair growth in mice is not synchronized and occurs in waves, resulting in different stages of hair follicles being present in close proximity. The stochasticity of hair growth waves in mice can lead to misconceptions in mutant or drug-treated mice. This article provides guidelines for designing reliable murine hair growth studies and highlights experimental caveats to be avoided.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Hsien-Yi Chiu, Joung-Liang Lan, Ying-Ming Chiu
Summary: This study estimated the cumulative incidence rate, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for incident psoriasis using real-world nationwide data from Taiwan. The lifetime risk of psoriasis decreased over the years, and male patients had higher lifetime and annual lifetime healthcare expenditures than female. Younger patients had relatively higher mean life expectancy, loss-of-life expectancy, and lifetime cost.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2023)
Article
Chemistry, Multidisciplinary
Kai-Chiang Yu, Chun-Yao Hsu, Gurpur Rakesh D. Prabhu, Hsien-Yi Chiu, Pawel L. Urban
Summary: Skin metabolites have promising potential for clinical diagnostics, but current sampling and analysis methods are time-consuming. In this study, researchers developed a vending-machine-style platform that uses hydrogel-assisted sampling to collect skin metabolites. The platform involves a robotic arm holding a sampling probe with hydrogel, which is pressed onto the forearm to capture water-soluble metabolites. The probe is then analyzed using a high-resolution mass spectrometer, with results displayed on a user interface.
Review
Pharmacology & Pharmacy
Hsien-Yi Chiu, Yi-Teng Hung, Shi-Wei Huang, Yu-Huei Huang
Summary: The meta-analysis found that corticosteroids, infliximab, JAK inhibitors (tofacitinib), and some combination therapies were associated with a higher risk of herpes zoster in patients with psoriasis. Meanwhile, phosphodiesterase-4 inhibitors, anti-interleukin-17, -23 or -12/23, phototherapy, and acitretin showed a risk similar to the control group.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2022)